Document:

EX-10.16

 Exhibit 10.16 

EMPLOYMENT AGREEMENT 
 THIS
EMPLOYMENT AGREEMENT (the “Agreement”) is made effective the 23rd day of October, 2016 (the “Effective Date”), by and between JULIEN L. PHAM, M.D., M.P.H. (the
“Employee”), and GENPREX, INC., a Delaware corporation (“Genprex”). 
  

	1.	EMPLOYMENT 

 Section 1.01. Employment. Genprex hereby employs Employee, and
Employee hereby accepts employment by Genprex upon the terms and conditions contained in this Agreement. 
 Section 1.02. Position
and Duties. 
 (a) Position. During the Term (as defined herein) of this Agreement, Employee shall serve Genprex
as Chief Operating Officer with duties and responsibilities that are commensurate with such office as shall from time to time be determined by the board of directors of Genprex (the “Board”) and/or Genprex’s Chief Executive Officer
(“CEO”) and as set forth in Section 1.02(b) of this Agreement. 
 (b) Duties. During the Term of this
Agreement, Employee shall devote substantially all of his business time, energy, and skill to performing services as Chief Operating Officer of Genprex. Employee shall have such duties as are generally associated with his office and as shall be
designated from time to time by the CEO or the Board. Employee shall at all times act honestly, with reasonable care, and with loyalty to Employer. 

(c) Conflicting Activities. 

(i) During the Term of this Agreement, Employee shall not be engaged in any other business activity without the prior consent
of the CEO or the Board; except that Employee may: (a) invest his personal assets in publicly traded stock of business entities that are not in competition with Genprex or its affiliates; (b) participate in the clinical practice of
medicine for up to three days per month (or more, if approved by the CEO); (c) be involved as an adjunct professor or in another capacity with Dell Medical School or other academic entities that are approved by the CEO; and/or (d) invest in
other opportunities that do not involve development of drugs for treatment of cancer and in which Employee does not have a management role; provided that the activities described in (a)-(d) in this subsection do not materially interfere with
Employee’s duties as an officer of Genprex. 
 (ii) During the Term of this Agreement, Employee hereby agrees to promote
and develop all opportunities that come to his attention relating to current or anticipated future business of Genprex, in the manner requested by the CEO or the Board. Should Employee discover a business opportunity that does

  

			
	Julien L. Pham Employment Agreement	  	Page 1

 
not relate to the current or anticipated future business of Genprex (hereinafter referred to as an “Unrelated Opportunity”), he shall first offer such opportunity to Genprex. Should the
Board not exercise its right to pursue such Unrelated Opportunity within a reasonable period of time, not to exceed sixty (60) days from the date Employee offers such Unrelated Opportunity to Genprex, then Employee may develop such Unrelated
Opportunity for himself; provided, however, that such development may in no way conflict or interfere with the duties owed by Employee to Genprex under this Agreement. Further, Employee may develop such Unrelated Opportunity only on
his own time, without violating the agreements set forth in Section 1.02(b) of this Agreement, and may not use any service, personnel, equipment, supplies, facility, or trade secrets of Genprex in the development of such Unrelated Opportunity.

  

	2.	TERM 

 Section 2.01. Term of Agreement. The term of this Agreement shall
commence on the Effective Date and shall continue until such time as the Agreement is terminated in accordance with the provisions set forth in Section 2.02 of in this Agreement. (Such period of time is referred to in this Agreement as the
“Term”). 
 Section 2.02. At-Will Status. This is an “At Will”
employment agreement. Nothing in Genprex’s policies, actions, or this document shall be construed to alter the “At Will” nature of Employee’s status with Genprex, and Employee understands that Genprex may terminate his employment
at any time, with or without prior notice, for any reason or for no reason, provided it does not do so in violation of state or federal law. Employee may terminate this Agreement at any time, with or without prior notice. 

Section 2.03. Return of Property. Upon the termination of this Agreement, for any reason, or at any other time that Genprex so
requests, Employee will turn over to Genprex all property of Genprex and all Proprietary Information in any form. Employee agrees that he will not keep any copies of such materials. 

 

	3.	COMPENSATION 

 Section 3.01. Base Compensation. During the term of this
Agreement Genprex shall initially pay to Employee base compensation (the “Base Compensation”) of $23,750 per month. Employee will also receive an initial grant of stock options under Genprex’s stock option plan. Employee’s Base
Compensation shall be payable in accordance with Genprex’s customary payroll practices but in no event less often than monthly. Genprex shall be entitled to withhold any compensation to be paid pursuant to this Section on account of payroll
taxes, income taxes, and other similar matters as are required to be withheld by applicable law. 

  

			
	Julien L. Pham Employment Agreement	  	Page 2

 Section 3.02 Bonus. In the event the Employee is employed for at least one year and
during the first year of employment Genprex receieves at least $12 million of funding, excluding funding from government sources, the Employee will receive a bonus of $65,000.00. 

Section 3.02 Severance Pay. If employed for at least on year and Employee terminates his employment for Good Reason (defined
below) or Genprex terminates his employment without Cause (defined below), and provided that Genprex has at least $5 million in cash or cash equivalents and a net worth of at least $5 million under generally accepted accounting principles
on the date of termination, then Employee will receive a severance payment equal to six months of his salary as of the date of termination. “Good Reason” for termination means (a) Employee is not paid compensation when due hereunder;
(b) Employee’s job title is changed without his consent; or (c) there is a change in control of Genprex, defined as follows: (i) Genprex and/or shareholders acting in concert sell a majority of Genprex’s issued and
outstanding voting shares in one transaction or a series of coordinated transactions to a single buyer or a group of buyers acting in concert with one another, or (ii) Genprex sells substantially all of its asses. “Cause” for
termination by Genprex means: (i) Employee is not performing or cannot perform his duties as described hereinto the reasonable satisfaction of the CEO and the Board, or (ii) Employee breaches this Agreement. 

Section 3.02. Source of Compensations. Employee hereby acknowledges and agrees that Genprex’s obligation to pay the amounts
referenced in Section 3.01 of this Agreement represents an unfunded and unsecured obligation of Genprex, shall be paid in cash from the general funds of Genprex, and, except as required by law, no special or separate fund shall be established
and no other segregaton of assets shall be made to assure payment. Employee shall have no right, title, or interest whatever in or to any investments which Genprex may make and Employee shall have no right, title, or interest whatever in or to any
investments made by any person in Genprex. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind, or a fiduciary relationship from Genprex to Employee or any
other person. To the extent that any person acquires a right to receive payments from Genprex hereunder, such right shall be no greater than the right of an unsecured creditor of Genprex. 

4. EMPLOYMENT BENEFITS AND REIMBURSEMENTS 

Section 4.01. Personal Time Off (“PTO”). Employee shall be entitled to fifteen (15) days with pay for each twelve
(12) month period of employment completed by Employee; provided, however, that Employee must utilize such PTO within the twelve (12) month period following the date the PTO is earned. Notwithstanding the foregoing, Employee
may carry over up to five (5) days of PTO from the twelve (12) month period in which such time was earned to the immediately succeeding twelve (12) month period. 

Section 4.02. Miscellaneous Benefits. During the Term of this Agreement, Employee shall be entitled to participate in any group
life insurance plan, hospitalization insurance plan, medical services plan, disability insurance plan, or any other plan or arrangement of Genprex now or hereafter (during the Term) existing for the benefit of employees generally, subject to the
terms of each such plan. 

  

			
	Julien L. Pham Employment Agreement	  	Page 3

 Section 4.03. Reimbursement of Expenses. During the Term of this Agreement, Employee
shall be reimbursed for all reasonable “out-of-pocket” business expenses for business travel and business entertainment incurred in connection with the
performance of his duties under this Agreement. The reimbursement of Employee’s business expenses shall be upon presentation to and approval by Genprex of valid receipts and other appropriate documentation for such expenses. 

 

	5.	OWNERSHIP; RIGHTS; PROPRIETARY INFORMATION; PUBLICITY 

 Section 5.01. Ownership
of Inventions. Genprex shall own all right, title, and interest (including patent rights, copyrights, trade secret rights, trademark rights, sui generis database rights, and all other intellectual and industrial property rights of any
sort throughout the world) relating to any and all inventions (whether or not patentable), works of authorship, designations, designs, know-how, ideas, and information made or conceived or reduced to practice,
in whole or in part, by Employee during the term of this Agreement that relate to the subject matter of, or arise out of, the Services or any Proprietary Information (as defined below) (collectively referred to herein as the “Inventions”)
and Employee will promptly disclose and provide all Inventions to Genprex. All Inventions are work made for hire to the extent allowed by law and, in addition, Employee hereby makes all assignments necessary to accomplish the foregoing ownership;
provided, however, that no assignment is made that extends beyond what is allowed under applicable law. Employee shall further assist Genprex, at Genprex’s expense, to further evidence, record, and perfect such assignments, and to
perfect, obtain, maintain, enforce, and defend any rights assigned. Employee hereby irrevocably designates and appoints Genprex and its executive officers as its agents and
attorneys-in-fact to act for and in Employee’s behalf to execute and file any document and to do all other lawfully permitted acts to further the foregoing with the
same legal force and effect as if executed by Employee. 
 Section 5.02. Proprietary Information. Employee agrees that all
Inventions and all other business, technical, and financial information (including, without limitation, the identity of and information relating to customers or employees) Employee develops, learns, or obtains during the period over which it is (or
is supposed to be) providing Services that relate to Genprex or the business or demonstrably anticipated business of Genprex or that are received by or for Genprex in confidence, constitute “Proprietary Information.” Employee will hold in
confidence and not disclose or, except in performing the Services, use any Proprietary Information; provided, however, that Employee shall not be obligated under this paragraph with respect to information that is or becomes readily
publicly available without restriction through no fault of Employee. Upon termination and as otherwise requested by Genprex, Employee will promptly return to Genprex all items and copies containing or embodying Proprietary Information, except that
Employee may keep its personal copies of its compensation records and this Agreement. Employee also recognizes and agrees that Employee has no expectation of privacy with respect 

  

			
	Julien L. Pham Employment Agreement	  	Page 4

 
to Genprex’s telecommunications, networking or information processing systems (including, without limitation, stored computer files, e-mail messages,
and voice messages) and that Employee’s activity, and any files or messages, on or using any of those systems may be monitored at any time without notice. 

Section 5.03. Restrictions. As additional protection for Proprietary Information, Employee agrees that during the period over
which it is (or is supposed to be) providing Services and for one year thereafter, Employee will not encourage or solicit any employee or consultant of Genprex to leave Genprex for any reason and will not engage in any activity that is in any way
competitive with the business or demonstrably anticipated business of Genprex, and Employee will not assist any other person or organization in competing or in preparing to compete with any business or demonstrably anticipated business of Genprex.

 Section 5.04. Royalty-Free License. If any part of the Services or Inventions is based on, incorporates, or is an improvement
or derivative of, or cannot be reasonably and fully made, used, reproduced, distributed, and otherwise exploited without using or violating technology or intellectual property rights owned or licensed by Employee and not assigned hereunder, Employee
hereby grants Genprex and its successors a perpetual, irrevocable, worldwide royalty-free, non-exclusive, sublicenseble right and license to exploit and exercise all such technology and intellectual property
rights in support of Genprex’s exercise or exploitation of the Services, Inventions, other work performed hereunder, or any assigned rights (including any modifications, improvements, and derivatives of any of them). 

 

	6.	MISCELLANEOUS 

 Section 6.01. Right of
Set-Off. Genprex shall have the right to set-off against any of the amounts due Employee hereunder the amount of any outstanding loan or advance from Genprex to
Employee or any other outstanding amounts owed by Employee to Genprex. 
 Section 6.02. Amendment. This Agreement may be
amended, modified, superseded, or canceled, and any of the terms, provisions, covenants or conditions hereof may be waived only by a written instrument executed by Employee and the Board or, in the case of a waiver, by the party waiving compliance.

 Section 6.03. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be
an original but all of which together will constitute one and the same instrument. 
 Section 6.04. No Waiver. Neither the
failure nor any delay on the part of either party to exercise any right, remedy, power, or privilege under this Agreement shall operate as a waiver thereof nor shall any single of partial exercise of any right, remedy, power, or privilege preclude
any other of further exercise of the same or of any right, remedy, power, or privilege, nor shall any waiver any of right, remedy, power, or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power, or privilege
with respect to any other occurrence. 

  

			
	Julien L. Pham Employment Agreement	  	Page 5

 Section 6.05. Notices. All notices, requests, demands, and other communication
required or permitted under this Agreement and the transactions contemplated herein shall be in writing and shall be deemed to have been duly given, made and received when, (a) personally delivered, (b) one (1) business day after it is
sent by overnight service, or (c) two (2) business days after it is sent by first class mail, postage prepaid, by certified mail return receipt requested, addressed as set forth opposite each party’s name on the signature page of this
Agreement. Any party may alter the address to which communications or copies are to be sent by giving notice of such change of address in conformity with the provisions of this subsection for the giving of notice, which shall be effective only upon
receipt. 
 Section 6.06. Provisions Separable. The provisions of this Agreement are independent of and separable from each
other, and no provision shall be affected or rendered invalid or unenforceable by virtue of the fact that for any reason any other or others of them may be invalid or unenforceable in whole or in part. 

Section 6.07. Entire Agreement. This Agreement contains the entire understanding between the parties hereto with respect to the
subject matter hereof and supersedes all prior and contemporaneous agreements and understandings, inducements or conditions, express or implied, oral or written except as herein contained. 

Section 6.08. Headings; Index. The headings of paragraphs are included solely for convenience of reference and shall not control
the meaning or interpretation of any of the provisions of this Agreement. 
 Section 6.09. Governing Law, Jurisdiction and
Venue. This Agreement shall be governed by and construed in accordance with the laws of the State of Texas, without reference to any conflicts of laws provisions. Exclusive venue for the litigation of any dispute relating to this Agreement shall
lie in the courts of the United States of America and the State of Texas located in the Travis County, Texas; and each party hereto consents to the personal jurisdiction of such courts with respect to all such matters. 

Section 6.10. Waiver of Jury Trial. EACH PARTY, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY IRREVOCABLY WAIVES ALL
RIGHT TO TRIAL BY JURY AS TO ANY ISSUE RELATING HERETO IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER MATTER INVOLVING THE PARTIES HERETO. 

Section 6.11. Survival. The covenants and agreements of the parties set forth in Sections 5 and 6 of this Agreement are of a
continuing nature and shall survive the expiration, termination, or cancellation of this Agreement, regardless of the reason therefor. 

  

			
	Julien L. Pham Employment Agreement	  	Page 6

 Section 6.12. Binding Effect; Assignment. This Agreement shall be binding upon and
inure to the benefit of and be enforceable by the parties hereto and their respective successors and assigns, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or
assets of Genprex, spouses, heirs, and personal and legal representatives. Employee hereby acknowledges that the services to be rendered by Employee under this Agreement are unique and personal. Therefore, Employee may not assign any rights or
delegate any duties under this Agreement without the prior written consent of the Board. 
 Section 6.13. Cumulative Remedies.
Each and all of the several rights and remedies provided in this Agreement, or by law or in equity, shall be cumulative, and no one of them shall be exclusive of any other right or remedy, and the exercise of any one of such rights or remedies shall
not be deemed a waiver of, or an election to exercise, any other such right or remedy. 
 Section 6.14. Independent Counsel.
Employee hereby acknowledges and agrees that he has had reasonable opportunity to consult with separate counsel with respect to the matters contained herein and is not relying on any representations of any party with respect to the terms of this
Agreement not otherwise contained herein. 
 Signed to be effective upon the date first written above. 

 

			
	GENPREX, INC.
		
	By:	 	 /s/ RODNEY VARNER

		 	Rodney Varner, CEO
	
	 /s/ JULIEN L. PHAM, M.D., M.P.H.

	Julien L. Pham, M.D., M.P.H.

  

			
	Julien L. Pham Employment Agreement	  	Page 7EX-10.1

 Exhibit 10.1 

COOPERATION AGREEMENT 

This Cooperation Agreement (this “Agreement”) is made and entered into as of August 17, 2017 by and among SeaChange
International, Inc. (the “Company”) and the entities and natural persons set forth in the signature pages hereto (collectively, “Viex”) (each of the Company and Viex, a “Party” to this Agreement,
and collectively, the “Parties”). 
 RECITALS 

WHEREAS, as of the date hereof, Viex is deemed to beneficially own shares of the Company’s common stock, $0.01 par value per share (the
“Common Stock”), totaling, in the aggregate, 3,875,956 shares, or approximately 11.0% of the Common Stock issued and outstanding on the date hereof; and 

WHEREAS, as of the date hereof, the Company and Viex have determined to come to an agreement to modify the composition of the Board of
Directors of the Company (the “Board”) and as to certain other matters relating to, among other things, the Company’s 2018 annual meeting of stockholders (the “2018 Annual Meeting”), as provided in this
Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound hereby, agree as follows: 

Section 1. Board Matters, Appointment of Director and Related Agreements. 

(a) Appointment of the New Independent Director. Promptly following the execution of this Agreement, the Company shall take all
necessary actions to appoint Mark Bonney to serve as a Class I director of the Company (the “New Independent Director”) with a term expiring at the 2018 Annual Meeting. As a condition to appointment of the New Independent
Director the following conditions (the “Appointment Conditions”) shall have been satisfied with respect to such designee: (i) such person shall have been determined in good faith by the Corporate Governance and Nominating
Committee of the Board and by the Board to qualify as “independent” pursuant to the Securities and Exchange Commission (“SEC”) and NASDAQ listing standards, to have relevant financial and business experience to serve on
the Board and not to be an Affiliate or Associate of Viex (as such terms are defined in Section 2 below), and (ii) such person shall have entered into an agreement with the Company in the form
attached as Exhibit A hereto (the “Director Agreement”), pursuant to which such person agrees to (A) comply with all Company policies, procedures, processes, codes, rules, standards and guidelines applicable to
all Board members, including the Company’s code of ethics and business conduct, securities trading policies, director confidentiality policies, and corporate governance guidelines; (B) preserve the confidentiality of Company business and
information, including discussions of matters considered in meetings of the Board or Board committees; and (C) complete the Company’s customary director and officer questionnaire and other reasonable and customary onboarding documentation
and procedures required by the Company in connection with the election or appointment of Board members, and such shall have been completed. 

(b) Nomination of the New Independent Director. So long as Viex continues to beneficially own at least three percent (3%) of the then
issued and outstanding Common Stock (the “Minimum Ownership Threshold”) and Viex shall not have been found to have materially breached its obligations pursuant to this Agreement (as determined by a court of competent jurisdiction in
a final and non-appealable decision), the Board and the appropriate committee(s) of the Board shall take all necessary actions to nominate and recommend the New Independent Director for election at the 2018
Annual Meeting for a term expiring at the Company’s 2021 annual meeting of stockholders. 
 (c) Replacement Director. So long as
Viex continues to satisfy the Minimum Ownership Threshold, and Viex shall not have been found to have materially breached its obligations pursuant to this Agreement (as determined by a court of competent jurisdiction in a final and non-appealable decision), in the event the New Independent Director is unable to serve as a director, resigns as a director or is removed prior to the termination or expiration of the Standstill Period, Viex shall
have the right to recommend a replacement director to 

 
the Board. The appointment of any such person to the Board shall be subject to approval of the Corporate Governance and Nominating Committee of the Board and the Board after exercising its
fiduciary duties in good faith, which approval shall not be unreasonably withheld (any such replacement nominee appointed in accordance with the terms of this Section will be referred to herein as the “Replacement Director” and
references herein to the “New Independent Director” shall be deemed a reference to the “Replacement Director”), and the Appointment Conditions having been satisfied with respect to the Replacement Director. In the event the
Corporate Governance and Nominating Committee of the Board and the Board do not accept the Replacement Director recommended by Viex, the Parties will continue to follow the procedures of this
Section 1(c) until a Replacement Director is appointed or elected to the Board, provided Viex continues to be eligible to appoint a Replacement Director pursuant to the first sentence of this
Section 1(c). 
 (d) Director Compensation. The Company agrees that the New Independent
Director or any Replacement Director shall receive (i) the same benefits of director and officer insurance, and any indemnity and exculpation arrangements available generally to the directors on the Board, (ii) the same compensation for
his service as a director as the compensation received by other non-management directors on the Board, and (iii) such other benefits on the same basis as all other
non-management directors on the Board. 
 (e) Director Resignation. Concurrent with and as a
condition to effectiveness of this Agreement, Steven Craddock shall have resigned as member of the Board, chairman of the Board and from any committees of the Board. 

Section 2. Covenants. 
 (a) Viex
agrees that it will cause its controlled Affiliates and Associates to comply with the terms of this Agreement and shall be responsible for any breach of this Agreement by any such controlled Affiliate or Associate. As used in this Agreement, the
terms “Affiliate” and “Associate” shall have the respective meanings set forth in Rule 12b-2 promulgated by the SEC under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) and shall include all persons or entities that at any time during the term of this Agreement become Affiliates or Associates of any person or entity referred to in this Agreement. 

(b) During the term of the Standstill Period (defined below), Viex agrees that it will appear in person or by proxy at any meeting of the
Company’s stockholders and vote all shares of Common Stock of the Company beneficially owned by Viex at the meeting in favor of any proposal supported by a majority of the Board; provided, however, that Viex shall have the right
to vote in accordance with the recommendation of Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) with respect to any matter, other than nominees for election as directors to the
Board, for which the recommendation of both ISS and Glass Lewis differs from the Board’s recommendation; provided, further, that Viex shall have the right to vote in its sole discretion with respect to any Extraordinary
Transaction (as defined below) if such Extraordinary Transaction is not supported unanimously by the Board. 
 Section 3. Standstill Provisions.

 Viex agrees that from the date of this Agreement until 11:59 p.m., Eastern Time, on August 30, 2018 (the “Standstill
Period”), neither it nor any of its Affiliates or Associates under its control or direction will, and it will cause each of its Affiliates and Associates under its control and direction not to, directly or indirectly, in any manner: 

(a) purchase or cause to be purchased or otherwise acquire or agree to acquire beneficial ownership of any Common Stock or other securities
issued by the Company, or any securities convertible into or exchangeable for Common Stock, such that Viex, together with its Affiliates and Associates would, in the aggregate, beneficially own a number of shares in excess of fifteen percent (15.0%)
of the then outstanding shares of Common Stock; 

  
 - 2 - 

 (b) engage in any solicitation of proxies or consents or become a “participant” in a
“solicitation” (as such terms are defined in Regulation 14A under the Exchange Act) of proxies or consents, in each case, with respect to securities of the Company; 

(c) form, join or in any way participate in any “partnership, limited partnership, syndicate or other group” (within the meaning of
Section 13(d)(3) of the Exchange Act) with respect to the Common Stock (other than a “partnership, limited partnership, syndicate or other group” that includes all or some of the persons identified on Exhibit B and their
Affiliates, but does not include any other entities or persons not identified on Exhibit B as of the date hereof); 
 (d) grant
any proxy, consent or other authority to vote with respect to any matters (other than to the named proxies included in the Company’s proxy card for any annual meeting or special meeting of stockholders) or deposit any Common Stock in any voting
trust or subject any Common Stock to any arrangement or agreement with respect to the voting of any Common Stock, other than any such voting trust, arrangement or agreement solely among the members of Viex and otherwise in accordance with this
Agreement; 
 (e) seek, or encourage any person, to submit nominations in furtherance of a “contested solicitation” for the
election or removal of directors with respect to the Company or seek, encourage or take any other action with respect to the election or removal of any directors; 

(f) (A) make any proposal (binding or non-binding) for consideration by stockholders at any annual
or special meeting of stockholders of the Company or participate in any proposal made by any third party, (B) conduct a referendum of stockholders, (C) make a request for any stockholder list materials or any books and records of the
Company or any of the Company’s Affiliates or Associates whether pursuant to Section 220 of the Delaware General Corporation Laws or otherwise, (D) make or, other than as unanimously supported by the Board, participate in any offer or
proposal (with or without conditions and whether public or private) with respect to any merger, acquisition, recapitalization, restructuring, disposition, distribution, spin-off, asset sale, joint venture or
other business combination involving the Company or of any of its Affiliates (an “Extraordinary Transaction”), or encourage, initiate or support any other third party with respect to any of the foregoing, (E) make any public
communication in opposition to any Extraordinary Transaction approved by the Board, (F) call or seek to call a special meeting of stockholders of the Company, or (G) initiate, encourage or participate in any “vote no”,
“withhold” or similar campaign with respect to any annual or special meeting of the stockholders of the Company, directly or indirectly; 

(g) seek, alone or in concert with others, representation on the Board or the removal of any member of the Board, except as specifically
permitted in this Agreement; 
 (h) seek to advise, encourage, support or influence any person with respect to the voting or disposition of
any securities of the Company at any annual or special meeting of stockholders; 
 (i) institute, solicit, assist or join, as a party, any
litigation, arbitration or other proceeding against or involving the Company or any of its current or former directors or officers (including derivative actions) other than (A) litigation by Viex to enforce the provisions of this Agreement,
(B) counterclaims with respect to any proceeding initiated by, or on behalf of, the Company or its Affiliates against Viex and (C) the exercise of statutory appraisal rights; 

(j) disclose that Viex voted contrary to the recommendation of the Board on any matter before a meeting of stockholders of the Company, other
than a vote at a meeting of stockholders of the Company in connection with an Extraordinary Transaction; 
 (k) authorize, solicit, pay or
subsidize any third party to perform, act in concert with another person to, commit to, or agree in writing or otherwise to do, advise, assist or encourage any person in connection with, or enter into any discussions, negotiations, arrangements or
understandings with any person with respect to, any act prohibited in this Section 3; 

  
 - 3 - 

 (l) make any request or submit any proposal to amend or waive the terms of this Agreement or take
any other action regarding any of the types of matters addressed in this Section 3 that would, or would reasonably be expected to, trigger public disclosure obligations for any Party; or 

(m) disclose any intention, plan or arrangement inconsistent with any provision of this
Section 3. 
 Section 4. Representations and Warranties of the Company. 

The Company represents and warrants to Viex that (a) the Company has the corporate power and authority to execute this Agreement and to
bind it thereto, (b) this Agreement has been duly and validly authorized, executed and delivered by the Company, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the Company in accordance with
its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles,
(c) the execution, delivery and performance of this Agreement by the Company does not and will not (i) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to the Company, or (ii) result in any
breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right
of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which the Company is a party or by which it is bound and (d) the Company has not, directly
or indirectly, compensated or agreed to, and will not, compensate Steven Craddock in connection with his resignation from the Board pursuant to Section 1(e) with any cash, securities (including any
rights or options convertible into or exercisable for or exchangeable into securities or any profit sharing agreement or arrangement), or other form of compensation directly or indirectly related to the Company. The Company is not precluded under
this Section 4 from allowing the continued vesting of the Deferred Stock Units that Mr. Craddock and the other non-employee directors were granted on July 13, 2017 in accordance with past
Company policy and practice. 
 Section 5. Representations and Warranties of Viex. 

Viex represents and warrants to the Company that (a) the authorized signatory of Viex set forth on the signature page hereto has the power
and authority to execute this Agreement and any other documents or agreements to be entered into in connection with this Agreement and to bind Viex thereto, (b) this Agreement has been duly authorized, executed and delivered by Viex, and is a
valid and binding obligation of Viex, enforceable against Viex in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws
generally affecting the rights of creditors and subject to general equity principles, (c) the execution of this Agreement, the consummation of any of the transactions contemplated hereby, and the fulfillment of the terms hereof, in each case in
accordance with the terms hereof, will not conflict with, or result in a breach or violation of the organizational documents of Viex as currently in effect, (d) the execution, delivery and performance of this Agreement by Viex does not and will
not (i) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to Viex, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could
constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract,
commitment, understanding or arrangement to which Viex is a party or by which it is bound, (e) as of the date of this Agreement, Viex is deemed to beneficially own in the aggregate 3,875,956 shares of the Common Stock issued and outstanding on
the date hereof, (f) as of the date hereof, Viex does not currently have, and does not currently have any right to acquire or any interest in any other securities of the Company (or any rights, options or other securities convertible into or
exercisable or exchangeable (whether or not convertible, exercisable or exchangeable immediately or only after the passage of time or the occurrence of a specified event) for such securities or any obligations measured by the price or value of any
securities of the Company or any of its controlled Affiliates, including any swaps or other derivative arrangements designed to produce economic benefits and risks that correspond to the ownership of Common Stock, whether or not any of the foregoing
would give rise to beneficial ownership (as determined under Rule 13d-3 promulgated under the Exchange Act), and whether or not to be settled by delivery of Common Stock, payment of cash or by other
consideration, and without regard to any short position under any such contract or arrangement) and (g) Viex has not, directly or indirectly, compensated or agreed to, and 

  
 - 4 - 

 
will not, compensate the New Independent Director for his respective service as a director of the Company with any cash, securities (including any rights or options convertible into or
exercisable for or exchangeable into securities or any profit sharing agreement or arrangement), or other form of compensation directly or indirectly related to the Company or its securities. 

Section 6. Public Disclosure. 

Promptly following the execution of this Agreement, the Company shall issue a mutually agreeable press release (the “Press
Release”), the Company shall file a Current Report on Form 8-K and Viex shall file an amendment on Schedule 13D. Prior to the issuance of the Press Release and subject to the terms of this Agreement,
neither party shall otherwise issue a press release or public announcement regarding this Agreement or the matters contemplated hereby without the prior written consent of the other Party. During the Standstill Period, neither the Company nor Viex
shall make any public announcement or statement that is inconsistent with or contrary to the statements made in the Press Release, except (a) as required by law or the rules of any stock exchange (and, in any event, each Party will provide the
other Party, prior to making any such public announcement or statement, a reasonable opportunity to review and comment on such disclosure, to the extent reasonably practicable under the circumstances, and each Party will consider any comments from
the other in good faith), (b) with the prior written consent of the other Party, or (c) otherwise in accordance with this Agreement. 
 Section 7.
Expenses. 
 Each Party shall be responsible for its own fees and expenses in connection with the negotiation and execution of this
Agreement and the transactions contemplated hereby; provided, however, that the Company shall promptly reimburse Viex for its reasonable, documented
out-of-pocket fees and expenses of its outside legal counsel incurred in connection with the negotiation and execution of this Agreement and the transactions
contemplated hereby in an amount not to exceed in the aggregate $50,000. 
 Section 8. Specific Performance. 

Each of Viex, on the one hand, and the Company, on the other hand, acknowledges and agrees that irreparable injury to the other Party hereto
would occur in the event any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that such injury may not be adequately compensable by the remedies available at law (including
the payment of money damages). It is accordingly agreed that Viex (or any of the entities and natural persons listed in the signature pages hereto), on the one hand, and the Company, on the other hand (the “Moving Party”), shall
each be entitled to specific enforcement of, and injunctive relief to prevent any violation of, the terms hereof without the necessity of posting bond or other security, and the other Party hereto will not take action, directly or indirectly, in
opposition to the Moving Party seeking such relief on the grounds that any other remedy or relief is available at law or in equity. This Section 8 is not the exclusive remedy for any violation of this
Agreement. 
 Section 9. Severability. 

If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated. It is hereby stipulated and declared to be the
intention of the Parties that the Parties would have executed the remaining terms, provisions, covenants and restrictions without including any of such which may be hereafter declared invalid, void or unenforceable. In addition, the Parties agree to
use their best efforts to agree upon and substitute a valid and enforceable term, provision, covenant or restriction for any of such that is held invalid, void or enforceable by a court of competent jurisdiction. 

  
 - 5 - 

 Section 10. Notices. 

Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on
file by the sending Party); (iii) upon receipt, when sent by e-mail to the e-mail address for a Party set forth below; or (iv) one (1) business day after
deposit with a nationally recognized overnight delivery service, in each case properly addressed to the Party to receive the same. The addresses and facsimile numbers for such communications shall be: 

 

			
	 If to the Company:
	  	 SeaChange International, Inc.

		  	 50 Nagog Park

		  	 Acton, Massachusetts 01720

		  	 Attention: Edward Terino

		  	 Telephone: (978) 897-0100

		  	 Email: ed.terino @schange.com

		
	 With a copy to (which shall not constitute notice) to:
	  	 SeaChange International, Inc.

		  	 50 Nagog Park

		  	 Acton, Massachusetts 01720

		  	 Attention: David McEvoy

		  	 Telephone: (978) 897-0100

		  	 Email: dave.mcevoy@schange.com

  

			
		
	 If to Viex or any member thereof:
	  	 Viex Capital Advisors, LLC

		  	 825 Third Avenue, 33rd Floor

		  	 New York, New York 10022

		  	 Attention: Eric Singer

		  	 Telephone: (212) 752-5750

		  	 Email: singer@viexcapital.com

		
	 With a copy (which shall not constitute notice) to:
	  	 Olshan Frome Wolosky LLP

		  	 1325 Avenue of the Americas

		  	 New York, NY 10019

		  	 Attention: Steve Wolosky, Esq.

		  	 Telephone: (212) 451-2333

		  	 Facsimile: (212) 451-2222

		  	 Email: swolosky@olshanlaw.com

 Section 11. Applicable Law. 

This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without reference to the
conflict of laws principles thereof. Each of the Parties hereto irrevocably agrees that any legal action or proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any
judgment in respect of this Agreement and the rights and obligations arising hereunder brought by the other Party hereto or its successors or assigns, shall be brought and determined exclusively in the Delaware Court of Chancery and any state
appellate court therefrom within the State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any federal court within the State of Delaware). Each of the Parties hereto hereby irrevocably
submits with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees that it will not bring any action relating to this
Agreement in any court other than the aforesaid courts. Each of the Parties hereto hereby irrevocably waives, and agrees not to assert in any action or proceeding with respect to this Agreement, (i) any claim that it is not personally subject
to the jurisdiction of the above-named courts for any reason, (ii) any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice,
attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (iii) to the fullest extent permitted by applicable legal requirements, any claim that (A) the suit, action or proceeding in
such court is brought in an inconvenient forum, (B) the venue of such suit, action or proceeding is improper or (C) this Agreement, or the subject matter hereof, may not be enforced in or by such courts. 

  
 - 6 - 

 Section 12. Waiver of Jury Trial. 

EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.
EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION,
(B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION. 
 Section 13. Counterparts. 

This Agreement may be executed in two or more counterparts, each of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each of the Parties and delivered to the other Party (including by means of electronic delivery or facsimile). 

Section 14. Mutual Non-Disparagement. 

Subject to applicable law, each of the Parties covenants and agrees that, during the Standstill Period or if earlier, until such time as the
other Party or any of its agents, subsidiaries, affiliates, successors, assigns, officers, key employees or directors shall have breached this Agreement not cured on reasonable written notice or which, if cured, recurs, neither it nor any of its
respective agents, subsidiaries, affiliates, successors, assigns, officers, key employees or directors, shall (a) in any way publicly criticize, disparage, call into disrepute, comment negatively on or otherwise defame or slander any other
Party or any such other Party’s subsidiaries, affiliates, successors, assigns, current or former officers, current or former directors or employees, or any of their businesses, products or services, or (b) authorize, solicit, pay or
subsidize any third party to perform, act in concert with another person to, commit to, or agree in writing or otherwise to do, advise, assist or encourage any person in connection with, or enter into any discussions, negotiations, arrangements or
understandings with any person with respect to, any act prohibited by this Section. Notwithstanding the foregoing, nothing in this Section shall be deemed to prevent any Party from complying with a request for information from any governmental
authority with jurisdiction over the Party from whom information is sought, provided that, solely in the case of any disclosure that is proposed or required to appear in any required disclosure relating thereto, such Party must provide written
notice, to the extent legally permissible and practicable under the circumstances, to the other Party prior to making any such public disclosure and reasonably consider any comments of such other Party. 

Section 15. Confidentiality. 
 Viex
(with respect to itself and its Affiliates and Associates) hereby agrees, and the New Independent Director, and any Replacement Director, shall agree, that during such term as a member of the Board and thereafter, such person will not, without the
prior written consent of the Company, for any reason divulge to any third-party or use for his, her or its own benefit, or for any purpose other than the exclusive benefit of the Company, any information that would reasonably be deemed to be
confidential information of the Company or its Affiliates, including any confidential information of a third party made available to the Company or its Affiliates. Notwithstanding the foregoing, if any such person is compelled to disclose such
confidential information by court order or other legal process, to the extent permitted by applicable law, such person shall promptly so notify the Company so that it may seek a protective order or other assurance that confidential treatment of such
confidential information shall be afforded, and such person shall reasonably cooperate with the Company in connection therewith. If any such person is so obligated by court order or other legal process to disclose any such confidential information,
such person will disclose only the minimum amount of such confidential information as is necessary for such person to comply with such court order or other legal process. 

  
 - 7 - 

 Section 16. Entire Agreement; Amendment and Waiver; Successors and Assigns; Third Party
Beneficiaries. 
 This Agreement contains the entire understanding of the Parties hereto with respect to this subject matter. There are
no restrictions, agreements, promises, representations, warranties, covenants or undertakings between the Parties other than those expressly set forth herein. No modifications of this Agreement can be made except in writing signed by an authorized
representative of each the Company and Viex. No failure on the part of any Party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right,
power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by law. The terms and
conditions of this Agreement shall be binding upon, inure to the benefit of, and be enforceable by the Parties hereto and their respective successors, heirs, executors, legal representatives, and permitted assigns. No Party shall assign this
Agreement or any rights or obligations hereunder without, with respect to any member of Viex, the prior written consent of the Company, and with respect to the Company, the prior written consent of Viex. This Agreement is solely for the benefit of
the Parties hereto and is not enforceable by any other persons, other than the provisions of Section 14 for which the persons specified therein are intended third party beneficiaries of such provisions
and shall have all legal right and standing to enforce such provisions directly. 
 Section 17. Construction. 

When a reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement, unless otherwise indicated.
The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words “include,” “includes” and “including” are used
in this Agreement, they shall be deemed to be followed by the words “without limitation.” The words “hereof, “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this
Agreement as a whole and not to any particular provision of this Agreement. The word “will” shall be construed to have the same meaning as the word “shall.” The words “dates hereof” will refer to the date of this
Agreement. The word “or” is not exclusive. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms. Any agreement, instrument, law, rule or statute defined or referred to herein
means, unless otherwise indicated, such agreement, instrument, law, rule or statute as from time to time amended, modified or supplemented. 

Each of the Parties acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded the
execution of this Agreement, and that it has executed the same with the advice of said counsel. Each Party and its counsel cooperated and participated in the drafting and preparation of this Agreement and the documents referred to herein, and any
and all drafts relating thereto exchanged among the Parties shall be deemed the work product of all Parties and may not be construed against any Party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that
would require interpretation of any ambiguities in this Agreement against any Party that drafted or prepared it is of no application and is hereby expressly waived by each of the Parties, and any controversy over interpretations of this Agreement
shall be decided without regard to events of drafting or preparation. 
 [The remainder of this page intentionally left blank] 

  
 - 8 - 

 IN WITNESS WHEREOF, this Cooperation Agreement has been duly executed and delivered by the duly
authorized signatories of the Parties as of the date hereof. 
  

			
	SEACHANGE INTERNATIONAL, INC.
		
	By:	 	 /s/ Edward Terino

	Name:	 	Edward Terino
	Title:	 	Chief Executive Officer

 [Signature Page to Cooperation Agreement] 

 
			
	VIEX OPPORTUNITIES FUND, LP – SERIES ONE
		
	By:	 	 VIEX GP, LLC
 General Partner

		
	By:	 	 /s/ Eric Singer

		 	Name: Eric Singer
		 	Title: Managing Member
	
	VIEX GP, LLC
		
	By:	 	 /s/ Eric Singer

		 	Name: Eric Singer
		 	Title: Managing Member

  

			
	VIEX CAPITAL ADVISORS, LLC
		
	By:	 	 /s/ Eric Singer

		 	Name: Eric Singer
		 	Title: Managing Member

 [Signature Page to Cooperation Agreement] 

 
			
	VIEX SPECIAL OPPORTUNITIES FUND II, LP
		
	By:	 	 VIEX Special Opportunities GP II, LLC
 General
Partner

		
	By:	 	 /s/ Eric Singer

		 	Name: Eric Singer
		 	Title: Managing Member

  

			
	VIEX SPECIAL OPPORTUNITIES GP II, LLC
		
	By:	 	 /s/ Eric Singer

		 	Name: Eric Singer
		 	Title: Managing Member

  

	
	 /s/ Eric Singer

	ERIC SINGER

 [Signature Page to Cooperation Agreement] 

 EXHIBIT A 

Director Agreement 
 Agreement,
dated as of August 17, 2017 (the “Director Agreement”), by and between SeaChange International, Inc. (the “Company”) and Mark Bonney (“Mr. Bonney”) (each of the Company and
Mr. Bonney, a “Party” to this Director Agreement, and collectively, the “Parties”); 
 WHEREAS, as of
the date hereof, the Company has entered into a Cooperation Agreement (the “Cooperation Agreement”) with Eric Singer, Viex Capital Advisors, LLC and the other parties set forth on the signature pages thereto; 

WHEREAS, pursuant to the Cooperation Agreement, execution of this Agreement by Mr. Bonney is a condition precedent to the appointment to
Mr. Bonney to the Company’s board of directors (the “Board”); 
 NOW, THEREFORE, in consideration of the
foregoing premises and the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound hereby, agree
as follows: 
 1. Mr. Bonney hereby agrees to (A) comply with all Company policies, procedures, processes, codes, rules, standards and guidelines
applicable to all Board members, including the Company’s code of ethics and business conduct, securities trading policies, director confidentiality policies, and corporate governance guidelines; (B) preserve the confidentiality of Company
business and information, including discussions of matters considered in meetings of the Board or Board committees; and (C) complete the Company’s customary director and officer questionnaire and other reasonable and customary onboarding
documentation and procedures required by the Company in connection with the election or appointment of Board members. 
 2. This Director Agreement shall be
governed by and construed and enforced in accordance with the laws of the State of Delaware without reference to the conflict of laws principles thereof. Capitalized terms used herein that are not otherwise defined shall have the meaning set forth
in the Cooperation Agreement. Sections 8-17 of the Cooperation Agreement are hereby incorporated by reference herein, mutatis mutandis. 

IN WITNESS WHEREOF, this Director Agreement has been duly executed and delivered by the undersigned as the date first above written. 

SEACHANGE INTERNATIONAL, INC. 
  

							
	By: 	 		  	 	  	
	Name: Edward Terino	 		  	Mark Bonney, Individually	  	
	Title: Chief Executive Officer	 		  		  	

 EXHIBIT B 

Viex Opportunities Fund, LP – Series One 
 Viex Special
Opportunities Fund II, LP 
 Viex GP, LLC 
 Viex Special
Opportunities GP II, LLC 
 Viex Capital Advisors, LLC 
 Eric
Singer 

  
 - 13 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]